surufatinib plus cadonilimab

Phase 2Monoclonal antibody

surufatinib plus cadonilimab is one of 4 small molecule programs targeting Bile Duct Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct AdenocarcinomaActive, not recruiting

Bile Duct AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Bile Duct Adenocarcinoma

#DrugCompanyPhaseTrials

Surufatinib

HHutchison Medipharma Limited

Phase 2

—2

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

—3

surufatinib plus cadonilimab

ZZhejiang Cancer Hospital

Phase 2

1 4

Disitamab Vedotin Plus Cadonilimab

ZZhejiang Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bile Duct Adenocarcinoma1 trial

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT06092645·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for surufatinib plus cadonilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — surufatinib plus cadonilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for surufatinib plus cadonilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: ZZhejiang Cancer Hospital

surufatinib plus cadonilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bile Duct Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News